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Simple Summary: It is challenging for pathologists to diagnose primary gastrointestinal T-cell
neoplasms. Besides the rarity of the diseases, the small biopsy material makes it more difficult to dif-
ferentiate between non-neoplastic inflammation and secondary involvement of extra gastrointestinal
lymphoma. Since this group of diseases ranges from aggressive ones with a very poor prognosis to
indolent ones that require caution to avoid overtreatment, the impact of the diagnosis on the patient
is enormous. Although early treatment of aggressive lymphoma is essential, the treatment strategy
is not well established, which is a problem for clinicians. This review provides a cross-sectional
comparison of histological findings. Unlike previous reviews, we summarized up-to-date clinically
relevant information including the treatment strategies as well as practical differential diagnosis
based on thorough literature review.
Abstract: Primary gastrointestinal (GI) T-cell neoplasms are extremely rare heterogeneous disease
entities with distinct clinicopathologic features. Given the different prognoses of various disease
subtypes, clinicians and pathologists must be aware of the key characteristics of these neoplasms,
despite their rarity. The two most common aggressive primary GI T-cell lymphomas are enteropathy-
associated T-cell lymphoma and monomorphic epitheliotropic intestinal T-cell lymphoma. In ad-
dition, extranodal natural killer (NK)/T-cell lymphoma of the nasal type and anaplastic large cell
lymphoma may also occur in the GI tract or involve it secondarily. In the revised 4th World Health
Organization classification, indolent T-cell lymphoproliferative disorder of the GI tract has been incor-
porated as a provisional entity. In this review, we summarize up-to-date clinicopathological features
of these disease entities, including the molecular characteristics of primary GI T-cell lymphomas
and indolent lymphoproliferative disorders. We focus on the latest treatment approaches, which
have not been summarized in existing reviews. Further, we provide a comprehensive review of
available literature to address the following questions: How can pathologists discriminate subtypes
with different clinical prognoses? How can primary GI neoplasms be distinguished from secondary
involvement? How can these neoplasms be distinguished from non-specific inflammatory changes at
an early stage?
Keywords: primary gastrointestinal T-cell lymphoma; enteropathy-associated T-cell lymphoma;
EATL; monomorphic epitheliotropic intestinal T-cell lymphoma; MEITL; indolent T-cell lymphopro-
liferative disorder; ITLPD-GI; NK-cell enteropathy
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1. Introduction
The gastrointestinal (GI) tract is a common site for extranodal lymphoma involvement.
Primary GI lymphomas are predominately of the B-cell lineage, and T-cell neoplasms are
rare, accounting for 13–15% of GI lymphomas [1–3]. The majority (>90%) of primary GI
T-cell neoplasms exhibit aggressive behavior and are associated with short progression-free
survival and overall survival. In contrast, an indolent condition termed indolent T-cell
lymphoproliferative disorder of the GI tract (ITLPD-GI) has been identified. GI T-cell
lymphoma and lymphoproliferative disorders are heterogeneous entities consisting of
various subtypes with distinct clinicopathological features and prognoses. Therefore, both
clinicians and pathologists must be aware of the distinct characteristics of these lesions to
ensure that appropriate care is provided.
The revised 4th World Health Organization (WHO) classification in 2017 broadly
classifies primary GI T-cell lymphoma as enteropathy-associated T-cell lymphoma (EATL)
and monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL). In the 2001 WHO
classification, primary GI T-cell lymphoma with digestive symptoms was initially treated
as a separate category, termed enteropathy-type T-cell lymphoma (ETL). In 2008, the entity
was renamed EATL and further classified into type I and type II. Type I is associated
with celiac disease and has a high incidence in Northern Europe. Conversely, Type II
is not associated with celiac disease and has a higher incidence in Asian and Hispanic
populations [4]. Type I and type II EATLs differ clinically and morphologically, and also
exhibit distinct immunological and genetic features. In the revised 4th WHO classification,
EATL types I and II have been revised to EATL and MEITL, respectively [5].
In the revised 4th WHO classification, intestinal T-cell lymphoma, not otherwise
specified (ITL, NOS) and ITLPD-GI were newly defined. ITL, NOS is defined as T-cell lym-
phomas arising in the GI tract that are not otherwise specified as EATL, MEITL, anaplastic
large cell lymphoma, or extranodal natural killer (NK)/T-cell lymphoma. The clinical
course of ITL, NOS is generally aggressive, and this entity may include cases with in-
sufficient immunohistochemical evaluation and cases of secondary involvement of extra-
intestinal lymphoma. Currently, ITL, NOS is considered to be a provisional entity [6].
Extranodal NK/T-cell lymphoma of the nasal type (ENKTCL) and anaplastic large cell
lymphoma (ALCL) may also occur in the GI tract or involve it secondarily. Furthermore,
NK-cell enteropathy has been reported as a pseudomalignant lesion that is often misdiag-
nosed as lymphoma.
In this review, we summarize the clinical, histological, and immunophenotypic fea-
tures; molecular characteristics; and latest treatment approaches for primary GI T-cell
lymphoma and lymphoproliferative disorders. We provide a comprehensive review of
extant literature to answer the following questions: How can pathologists discriminate
subtypes with different clinical prognoses? How can primary GI neoplasms be distin-
guished from secondary involvement? How can these neoplasms be differentiated from
non-specific inflammatory changes at an early stage? This review comprehensively com-
pares and summarizes the histological findings of potential differential diseases and is
more practical than previous reviews. It also summarizes the latest treat approaches that
have not been summarized in existing reviews.
2. Enteropathy-Associated T-Cell Lymphoma
2.1. Definition and Epidemiology
EATL is a rare and aggressive intestinal T-cell lymphoma. The geographic distribution
of the incidence of EATL is distinct, with a high incidence in Europe and in individuals of
northern European descent. A previous report demonstrated that the proportion of EATL
in peripheral T-cell lymphoma was 9.1%, 5.8%, and 1.9% in Europe, North America, and
Asia, respectively [7]. EATL typically occurs in older individuals (60–70 years), and large
studies have reported either an equal sex distribution or slight male predominance (male:
female ratio of 1.04–2.8:1) [7–11].
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EATL is a complication of celiac disease [12,13], one of the most common genetic dis-
orders that affects approximately 1% of individuals worldwide [14], with a high prevalence
in Europe. Celiac disease is characterized by intolerance to dietary gluten that occurs in
individuals with HLA-DQ2 or DQ8, haplotypes of human leukocyte antigen (HLA) class
II [14]. The association between celiac disease and EATL was first established in a study
demonstrating that the HLA risk alleles (HLADQA1*0501 and DQB1*0201 (HLA-DQ2))
of celiac disease are present in majority of patients with EATL [15]. Moreover, serological
evidence of gluten sensitivity in patients with EATL has been reported [12]. Notably, a
gluten-free diet reduces the risk of lymphoma in patients with celiac disease [16].
2.2. Pathogenesis
EATL may be preceded by refractory celiac disease (RCD), which is defined as the
persistent or recurrent symptoms of malabsorption and mucosal damage despite a strict
gluten-free diet for over 12 months. Exclusion of other etiologies, including autoimmune
enteropathy, tropical sprue, and lymphoma, is mandatory to diagnose RCD [17]. RCDs
are biologically heterogeneous and can be divided into RCD type I (RCD I) and RCD type
II (RCD II) based on immunophenotypic and molecular characteristics of intraepithelial
lymphocytes (IELs). RCD I is characterized by increased polyclonal intraepithelial IELs of
normal immunophenotype (sCD3+, CD8+, and CD103+), whereas RCD II is characterized
by monoclonal IELs of aberrant immunophenotype (sCD3−, cCD3+, CD8−, CD5−, and
CD103+). IELs in celiac disease and RCD I show downregulated expression of CD5, but
they are not entirely CD5-negative, and they may have a mixture of CD5-positive and
negative subsets in some cases. Although the vast majority of RCD II show negative CD8,
some patients who meet the clinical criteria for RCD and show CD8 positivity have been
reported to show consistent monoclonality by PCR analysis of the TCR gene throughout
the follow-up [18]. Progression of RCD I to RCD II is considered to be rare [19], and the risk
of developing EATL is lower in RCD I (3–14% over 5 years) than in RCD II (33–52%) [20–24]
(Table 1).
Table 1. Comparison of celiac disease, RCD I, RCD II, and EATL [5,9,19–25].























Ki67 LI: high (>50%)
T-cell receptor polyclonal polyclonal monoclonal monoclonal
5-year survival 80–96% [18,20,21] 45–58% [18,20,21] ~20% [5,9,20]
Rate of progression to
EATL in 5 years 0.7% [24] 3–14% [19–23] 33–52% [19–23] -
Abbreviations: RCD; refractory celiac disease, EATL; enteropathy-associated T-cell lymphoma, sCD3; surface CD, cCD3; cytoplasmic CD,
Ki-67 LI; Ki-67 labeling index.
The NK receptor NKp46 was recently reported to be expressed in larger numbers of
IELs in RCD II and EATL, whereas only a few IELs were positive in celiac disease and RCD
I, suggesting that NKp46 may be a novel biomarker to clarify diagnosis [26].
Currently, two pathways are recognized for the pathogenesis of lymphoma, which are
associated with different clinical presentations and outcomes. EATL secondary to RCD II
(54% of all EATLs, according to one study [9]) is associated with severe GI symptoms and
higher mortality (5-year survival of 0–8%). In contrast, “de novo” EATL (46%), which occurs
in patients with uncomplicated celiac disease or RCD I, has higher survival rates (5-year
survival of 59%) [9,21]. Nevertheless, the pathogenesis of de novo EATL remains unclear.
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2.3. Cell Origin
Cells that proliferate in RCD and EATL were formerly thought to be thymic-derived
conventional intraepithelial T cells, which is T-cell receptor (TCR) αβ+, due to their im-
munophenotypic similarity to normal intraepithelial T-cells, which account for approxi-
mately 80% of IELs [9,27]. Recent molecular and immunophenotypic analyses suggest that
lineage-negative innate IELs are the origin of a proportion of RCD II cases [28–31], and
EATL arising from RCD II may have the same origin.
2.4. Histopathology
In EATL, diffuse proliferation of pleomorphic medium to large lymphoma cells is ob-
served. Lymphoma cells have abundant eosinophilic to pale cytoplasm and nuclei that are
round or irregular with distinct nucleoli. Infiltration of inflammatory cells, including histi-
ocytes, eosinophils, neutrophils, and plasma cells, is often present in the background [32].
Angiocentric proliferation and vascular invasion are present, and extensive necrosis associ-
ated with vascular occlusion is often observed [5,33]. The peripheral intestinal mucosa often
exhibits features of celiac disease such as intraepithelial lymphocytosis and villous atrophy.
2.5. Immunophenotype and Genetic Alternations
Neoplastic cells are typically CD3+ (cytoplasmic), CD5−, CD4−, CD56−, and diffusely
positive for cytotoxic granule proteins (TIA-1, granzyme B, and perforin) and intraepithe-
lial homing integrin CD103. CD8 tends to be negative but may be expressed in 19–30%
cases [4,9,34] and has been reported to be present at a higher frequency in patients with-
out a history of RCD II [9]. CD30 positivity depends on tumor cell morphology but is
almost exclusively positive in large cell-based tumors [9]. Neoplastic cells are negative for
anaplastic lymphoma kinase (ALK) and Epstein-Barr virus (EBV). Surface TCR expression
is typically absent, but intracellular TCRβ (βF1) expression is observed in approximately
25% of cases [9].
Several studies have used microsatellite markers or array-based approaches to detect
recurrent copy number gains at chromosomes 9q (the most common in EATL: 46–70%) [35–37],
7q, 1q, and 5q; and losses at chromosomes 16q, 8p, 13q, and 9p. Mutually exclusive gains
at 9q and losses at 16q are observed in up to 80% of EATL cases [35,37–39]. Moreover,
recent studies have reported recurrent mutations of the Janus kinase/signal transducer
and activator of transcription (JAK/STAT) pathway with frequent activating mutations in
STAT5B (26.5–29%), JAK1 (14.7–23%), JAK3 (23–27.3%), and STAT3 (12.1–16%) [36,40].
Targeted next-generation sequencing (NGS) of RCD II cases revealed recurrent activat-
ing mutation in JAK1 (75%) and STAT3 (25%) genes [30], which may implicate JAK-STAT
pathway mutations to be early events in EATL. Targeted NGS analysis of RCD II also
revealed frequent occurrence of deleterious mutations in nuclear factor kappa-light chain-
enhancer of activated B-cells (NF-κB) regulators and in several epigenetic regulators [41].
2.6. Clinical Manifestations
Approximately 90% of EATLs occur in the small intestine [7,8]. Multiple lesions occur
in 32–54% of cases, and single lesions in the stomach or colon are rare [7–9]. Given the
close association between EATL and celiac disease, symptoms such as diarrhea, abdominal
pain, weight loss, and hypoalbuminemia may precede EATL [7,9,10,42–44]. However, the
diagnosis of celiac disease is made prior to the diagnosis of EATL in 20–73% of cases [8,9,42].
EATL also causes vomiting due to intestinal obstruction, intestinal bleeding, and intestinal
perforation in 25–50% of patients [7–9,43–45]. Hemophagocytic syndrome is reported in
16–40% of cases [9,46].
EATLs can also spread beyond the GI tract, and the most common sites of involve-
ment are abdominal lymph nodes (35%), followed by bone marrow (3–18%), lung and
mediastinal lymph nodes (5–16%), liver (2–8%), and skin (5%) [7,9,10]. Involvement of the
central nervous system (CNS) has also been reported [47–49]. Endoscopically, EATL can
manifest as a large mass, ulceration, or stricture [7,9].
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2.7. Prognosis and Treatment Strategies
The prognosis of EATL is very poor. Gale et al. reported 1- and 5- year survival
rates of 38.7% and 9.7%, respectively, and 1- and 5-year failure-free survival rates of
19.4% and 3.2%, respectively [8]. Other studies have estimated 5-year survival rates of
11–20% [10,42,43,45,50]. Standard validated treatment strategies for EATL have yet to be
established. Surgery and chemotherapy are the treatments of choice, but EATL tends to be
refractory to these therapies [50]. CHOP (cyclophosphamide, hydroxydaunorubicin, on-
covin, and prednisolone) regimen is the most widely implemented approach, but its overall
median survival has been reported to be only 7 months [8,42,43,45]. Recently, autologous
stem cell transplant (ASCT) following chemotherapy has been reported to significantly
enhance survival [9,10,50–52]. One study demonstrated that the novel regimen IVE/MTX
(ifosfamide, vincristine, etoposide, methotrexate) followed by ASCT improved survival
rates compared to anthracycline-based chemotherapy, with a 5-year overall survival rate of
60% [10]. Although surgery is not considered as first-line treatment for lymphoma, tumor
reduction surgery has been reported to be an independent prognostic factor of nutritional
status [9]. Further, it is estimated that the combination of surgery and chemotherapy will re-
duce tumor necrosis, peritonitis, and intestinal hemorrhage associated with chemotherapy,
underscoring the potential of surgery as a treatment option at the appropriate time.
One case report of a CD30-positive patient with EATL demonstrated that targeted
therapy using brentuximab vedotin resulted in complete remission [53]. In another re-
port, a patient with EATL who had multiple relapses following ASCT achieved sustained
remission with CD30 chimeric antigen receptor-modified T-cell therapy [54].
For RCD, various immunosuppressive medications such as azathioprine, systemic
corticosteroids, or regular budesonide have been used. Although conventional immuno-
suppressive medications fail in about half of the cases, recent study revealed open-capsule
Budesonide has shown clinical and histological improvement in about 90% of the cases,
including those in which conventional treatments have failed [55]. Furthermore, in follow-
up, 53% of RCDII patients treated with open-capsule budesonide showed absence of the
former clonal TCR gene rearrangement and aberrant IEL phenotype. This indicates that
open-capsule budesonide may reduce the risk of developing from RCDII to EATL, although
longer follow-up is needed [55].
3. Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma (MEITL)
3.1. Definition and Epidemiology
Similar to EATL, MEITL is a primary GI T-cell lymphoma deriving from IELs with no
apparent association with celiac disease [56]. It occurs worldwide and is more common in
Asian and Hispanic populations than in western populations, accounting for the majority
of primary GI T-cell lymphomas in Asia [4,7,57–60]. MEITL is more common in the elderly,
with a median age of onset of 58–62 years (range: 23–89 years), and men are more commonly
affected than women (male: female ratio of approximately 2:1) [57–59].
3.2. Histopathology
Similar to EATL, lymphoma cells in MEITL infiltrate extensively into the intestinal
mucosal epithelium (Figure 1). MEITL comprises a monomorphic proliferation of relatively
small to medium-sized tumor cells with pale cytoplasm, round or slightly irregular nuclei,
poorly aggregated nuclear chromatin, and inconspicuous nucleoli. Tumor cell size varies
among patients, but cytology within the same tumor is monotonous. Compared to EATL,
necrosis and background inflammatory cell infiltration are less prominent.
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vere infiltration into the crypt epithelium is observed. Tumor cells are CD3-positive (c), CD5-nega-
tive (d), CD8-positive (e), and CD56-positive (f). 
The central zone (CZ) in the center of the tumor constitutes a site of destructive 
growth of lymphoma cells in the intestinal wall. In the CZ, tumor cells often infiltrate the 
entire GI wall, resulting in ulceration and perforation. The peripheral zone (PZ) is charac-
terized by lateral extension of tumor cells in the mucosa and submucosa, with less exten-
sive invasion of tumor cells into the muscularis propria than the CZ (Figure 2). Intraepi-
thelial lymphocytosis comprising >20 IELs per 100 epithelial cells, is observed further 
around the PZ but is indistinguishable from normal mucosa at low magnification in the 
Figure 1. Histological and immunohistochemical findings of monomorphic epitheliotropic intestinal
T-cell lymphoma. ((a, 10×, b, 40×), H&E) Diffuse proliferation of monomorphic lymphoid cells
with severe infiltration into the crypt epithelium is observed. Tumor cells are CD3-positive (c, 60×),
CD5-negative (d, 60×), CD8-positive (e, 60×), and CD56-positive (f, 60×).
The central zone (CZ) in the center of the tumor constitutes a site of destructive growth
of lymphoma cells in the intestinal wall. In the CZ, tumor cells often infiltrate the entire
GI wall, resulting in ulceration and perforation. The peripheral zone (PZ) is characterized
by lateral extension of tumor cells in the mucosa and submucosa, with less extensive
invasion of tumor cells into the muscularis propria than the CZ (Figure 2). Intraepithelial
lymphocytosis comprising >20 IELs per 100 epithelial cells, is observed further around the
PZ but is indistinguishable from normal mucosa at low magnification in the IEL zone. The
IEL zone may be located distant to the edge of the tumor, occasionally >10 cm away [59].
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Megakaryocyte-associated tyrosine kinase (MATK) is positive in 87% of tumor cells in 
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vation. A study from Hong Kong reported that 78% of MEITLs were of γδ origin [59]. 
Figure 2. ((a, low-power view), H&E) Jejunal resection demonstrating the central zone (CZ) character-
ized by transmural infiltration by lymphoma, the peripheral zone (PZ) characterized by lateral spread
of the lymphoma into the mucosa and submucosa, and the distant intraepithelial lymphocytosis
zone. ((b, 20×), H&E) The border area between PZ and intraepithelial lymphocytosis zone is shown.
In intraepithelial lymphocytosis zone, IELs show minimal atypia ((e, 60×), H&E) and are positive for
CD8 (c, 20×, f, 60×) and CD56 (d, 20×, g, 60×).
3.3. Immunophenotype and Genetic Alternations
Similar to EATL, tumor cells in MEITL are typically CD3+, CD5−, CD7+, CD4−,
TIA-1+, granzyme B+, perforin+, and CD103+. In contrast, most MEITL cells are CD8+
and CD56+, unlike EATL (Figure 1). Aberrant CD20 expression has been reported in
11–24% of cases, underscoring the need for caution in diagnosis [58,59]. CD30 is generally
negative [59]. Megakaryocyte-associated tyrosine kinase (MATK) is positive in 87% of
tumor cells in MEITL, and the extent of MATK expression has been reported to be useful
for differentiating MEITL from EATL [58,61].
MEITL is heterogeneous in terms of TCR expression, which can be of γδ or αβ
derivation. A study from Hong Kong reported that 78% of MEITLs were of γδ origin [59].
Among the reported cases, 6–33% lacked TCR expression (TCR silent), and dual expression
of TCR γ and β chains was observed in 16% of MEITL cases [57–59,62]. Unlike EATL,
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there is no association with HLADQA1*0501 and DQB1*0201 genotypes. Gains at 9q are
frequently observed in 70–80% of cases [37,62,63], and gains at the 8q24 locus (resulting
in MYC amplification) are also commonly observed (29–73%) [37,58]. Gains at 1q and 5q
are less common in MEITL than in EATL [37,64]. Further, alterations in SETD2 (a tumor
suppressor that encodes a lysine N-methyltransferase required for histone H3 lysine 36
trimethylation (H3K36me3)) are frequently observed (93–100% of cases), primarily with
loss-of-function mutations and/or loss of the corresponding locus [65,66]. As in EATL,
activating mutations in components of the JAK-STAT pathway are frequently observed
(76–83% of cases), with higher frequencies of mutations in JAK3 and STAT5B reported in
MEITL than in EATL [36,40,62,65].
3.4. Clinical Manifestations
The most common site of involvement in MEITL is the small intestine, especially the
jejunum [4,58,67]. The stomach, duodenum, and large intestine may also be affected, with
reported rates of 2.4–12.0%, 31%, and 8.3–23%, respectively [57,67,68]. Symptoms include
abdominal pain, diarrhea, weight loss, and GI hemorrhage [57,59]. Since MEITL is not
associated with celiac disease, there is typically no history of malabsorption, and it is often
detected after acute abdominal symptoms caused by intestinal obstruction or perforation.
Endoscopically, MEITL appears as a single or multiple masses, deep ulcers, superficial
ulcers, or relatively normal findings. Mass formation and superficial ulceration are most
frequently seen, in approximately 40% of cases [67].
3.5. Prognosis and Treatment Strategies
At the time of diagnosis, 31.6–33% of patients are in advanced Lugano stages [69] III–IV
and 23–24% of patients are in Ann-Arbor stages III–IV [57,58,70]. In a recent report, median
overall survival was 14.8 months (range: 2.4–27.2 months) [70], and 1-, 3-, and 5-year
survival rates were reported to be 36–57%, 26–32%, and 32%, respectively [57–59,68,70].
Standardized treatment strategies for MEITL have yet to be established. Similar to
EATL, CHOP therapy is widely adopted, but the response to treatment is poor. One study
reported that the complete remission (CR) rate for CHOP therapy was 37%, while the CR
rate for patients receiving other chemotherapies was 71% (p = 0.095) [70]. In this report,
non-CHOP chemotherapies included CHOEP (CHOP plus etoposide), ICE (ifosfamide, car-
boplatin, and etoposide), IMVP-16 (ifosfamide, methotrexate, etoposide, and prednisone),
EPOCH (etoposide, prednisolone, vincristine, cyclophosphamide, and doxorubicin), and
ESHAP (etoposide, methylprednisolone, (etoposide, methylprednisolone, cytarabine, and
cisplatin) [70]. Tse et al. reported that the CR rate was higher for L-asparaginase-based
regimens (60%) than for CHOP or anthracycline-based regimens (35%) [57]. Liu et al.
reported two cases of MEITL treated with chidamide (a new histone deacetylase inhibitor)
combined with chemotherapy with slightly improved survival time [71].
Among patients receiving ASCT (up-front and salvage), the 1- and 5-year overall
survival (OS) rates were 100% and 28%, respectively, which improved the prognosis [70].
However, these outcomes were unfavorable relative to the improvement in survival rates in
EATL reported in studies in Europe. Patients frequently experience local relapse in the GI
tract, and relapse in the CNS is occasionally observed (approximately 10% of cases) [70,72].
Although initial CNS prophylaxis is not generally recommended in patients with peripheral
T-cell lymphomas (PTCL), it may be beneficial in MEITL. Achieving CR and concurrent
ASCT may be essential for improving prognosis in patients with MEITL. However, many
patients are unable to tolerate the toxicity of treatment, and further studies are warranted
to determine the appropriate induction therapy for MEITL.
4. Intestinal T-Cell Lymphoma, Not Otherwise Specified (ITL, NOS)
4.1. Definition and Epidemiology
ITL, NOS is a group of aggressive primary GI T-cell lymphomas that do not meet any
of the diagnostic criteria for EATL, MEITL, ENKTCL, or ALCL [5]. This group may include
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entities for which the diagnosis cannot be confirmed due to insufficient immunostaining,
small biopsy specimens, or secondary involvement of extra-intestinal lymphoma. There-
fore, at present, it is considered a provisional entity [6]. This group may be reorganized
into specific disease categories of intestinal T-cell lymphoma as further findings in the clini-
copathologic and genetic spectrum become available [33]. With only a few epidemiological
studies specifically investigating this category, data on epidemiology are limited [2,6,60,73].
Despite the small number of cases, reports indicate that the mean age of patients is 44 years
and the proportion of patients older than 60 years is 21–32.4%. This entity is more prevalent
in men [2,60] and in Asia [60,73,74].
4.2. Immunophenotype and Genetic Alternations
As ITL, NOS is not considered a specific disease entity, histology and immunostaining
findings are not uniform. Reports indicate that the tumor cells have a medium to large size
and are frequently pleomorphic [60]. CD4+ or CD4−/CD8− double-negative phenotypes
are common [6,60]. CD8 and CD56 expression are low compared to that in MEITL [60].
EBV-positive cases are also noted in approximately 8% of cases [60]. TIA-1-positive cases
are common (92%), but the reported expression of granzyme B (42%) and CD30 (29%)
varies among studies [60]. TCR is silent or expresses TCRβ (βF1) in most cases [6,60]. Data
regarding genetic alterations in ITL, NOS are limited.
4.3. Clinical Manifestations
ITL, NOS can occur in any of the following regions: stomach (40%), small intestine
(20–38.2), ileum (20%), and colon (14.7–60%) [2,6]. No clear association with celiac disease
or GI symptoms has been reported to date [2,6]. Patients often present with extensive
extra-intestinal diseases at the time of diagnosis, but this may include lymphoid tumors
that are not primary to the intestine [2,60]. Clinical behavior tends to be aggressive, but
several reports have demonstrated better prognosis compared to EATL and MEITL (median
overall survival of 35 months) [2,60].
5. Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal
Tract (ITLPD-GI)
5.1. Definition and Epidemiology
ITLPD-GI is a newly defined provisional entity in the revised 4th edition of the
WHO classification [5]. The literature on low-grade T-cell LPD of the GI tract has been
limited to small case series and case reports [75–99]. The age distribution of patients is
15–77 years, and it is slightly more common in men than in women [84,85,87,90,100]. There
are no known ethnic or genetic risk factors. Several reports have suggested an association
of ITLPD-GI with inflammatory bowel disease (IBD), celiac disease, and autoimmune
enteropathy [87].
5.2. Histopathology
ITCLD-GI is characterized by dense, non-destructive infiltration of small monotonous
tumor cells into the lamina propria. Intraepithelial tumor cell infiltration is typically
absent [5,79,84,85,87,101] (Figure 3). Tumor cell infiltration occasionally extends into the
muscularis mucosae and submucosa, but mass formation or full-thickness involvement
of the intestinal wall are generally not observed [85]. Tumor cells exhibit minimal atypia
with small round nuclei, mature chromatin, and inconspicuous nucleoli [5,79,84,85,87,101].
A mixture of inflammatory cells is rare, but non-necrotizing epithelioid granulomas that
resemble histopathology of Crohn’s disease may be present in a subset of cases [79,87].
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5.3. I unophenotype and enetic lterations
I - I t or cells typically exhibit a CD2+, CD3+, CD5+, and CD4+ or CD8+
phenotype [5,79,84,85,90,101]. Although uncommon, CD4+/CD8+ (double-positive) [90]
and CD4−/CD8− (double-negative) [85] phenotyp s have been reported. In CD8+ cases,
TIA-1 is positive, but granzyme B is typically negative [85,86,90]. CD 6 [5,85,90] and EBV-
enco ed small RNA ( BER) in situ hybridization [5,85] are negative. CD30 [84,87,90,94]
and CD103 [77,79,81,83,88] are also negative, with rare exceptions. Ki-67 labeling rate
is very low (<10%) [5,84,85] (Figure 3). All cases exhibit a TCRβ (βF1)-positive pheno-
type [5,79,84,87,90,94]. All r ported ITLPD-GI cases harbor clonal rearrangements of TR
genes of TRG or TRB [84,85,87,90]. Although the molecular signatures underlying ITLPD-
GI are poorly understood, targeted NGS recently revealed that the CD4+, CD4+/CD8+,
and CD4−/CD8− ITLPD-GI cases harbored frequent alterations of JAK-STAT pathway
genes (5/6, 82%); STAT3 SH2 domain hotspot mutations (D661Y and S614R) (n = 3, 50%),
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SOCS1 deletion (n = 1, 16.7%), and STAT3-JAK2 rearrangement (n = 1, 16.7%) [102]. Another
study reported recurrent STAT3-JAK2 fusions in 80% (4/5 cases) of CD4+ ITLPD-GIs, with
evidence of STAT5 activation on immunostaining for pSTAT5Y694 [90].
5.4. Clinical Manifestations
ITLPD-GI can occur in any part of the GI tract, including the esophagus and oral
cavity, but is more common in the small intestine and colon [79,84,85,87]. Patients present
with diarrhea, abdominal pain, dyspepsia, vomiting and weight loss [79,84,85,87], and
symptoms may be misdiagnosed as non-specific gastroenteritis, CD, or IBD. Extrain-
testinal expansion beyond the mesenteric lymph nodes is rare [83–88], but several cases
involving the liver [79,87], bone marrow [83,86,87], and peripheral blood [87] have been
reported. Endoscopically, ITLPD-GI exhibits thickening of the wall, irregular mucosa,
and mucosal erosions. The surface of the mucosa is hyperemic with superficial ero-
sion [79,84,85,87]. Multiple small polypoid lesions resembling lymphomatous polyposis
are often reported [77,81,85].
5.5. Prognosis and Treatment Strategies
Progression is typically gradual, and patients have a chronic, refractory clinical course
for years to decades. Although ITLPD-GI does not usually respond to conventional
chemotherapy [79,84,85,87], steroids may improve symptoms [87]. Recently, a case of
ITLPD-GI confined to the stomach treated with relatively low-dose (30 Gy) “involved-field
radiation therapy” resulted in complete remission [97]. Although most patients have a
relatively favorable prognosis with monitoring, a small percentage of patients demonstrate
disease progression and transformation, typically after an interval of years, and cases with
a CD4+ phenotype are considered to be at higher risk [79,84,90,94]. The vast majority
of CD8+ ITLPD-GI are indolent disease, showing chronic course lasting for decades or
spontaneous regression [103], transformation into a higher-grade lymphoma has also been
reported in at least one case; Sharma et al. [90] reported a CD8+ ITLPD-GI that further
had systemic ALK negative ALCL. The optimal treatment for this disease has yet to be
established, and further case accumulation and long-term observations are needed. In
the future, the use of targeted agents that directly affect the JAK-STAT pathway may be
promising [104].
6. Differential Diagnoses and Diagnostic Pitfalls
6.1. Differential Diagnoses
Several aggressive T-cell and NK-cell lymphomas that typically arise outside the GI
tract, including ALCL, ENKTCL, and adult T-cell leukemia/lymphoma (ATLL), may also
involve the GI tract secondarily or primarily, although the latter is rare. NK-cell enteropathy
is a non-progressive NK-cell proliferation and should be correctly differentiated from
aggressive T-cell and NK-cell lymphoma. In addition, chronic active EBV infection (CAEBV)
of the gastrointestinal tract may also be a differential diagnosis. In this section, we briefly
describe these diseases and summarize points of differentiation.
6.1.1. Anaplastic Large Cell Lymphoma (ALCL)
According to the current WHO classification, ALCL is divided into three types ac-
cording to the presence or absence of ALK gene rearrangements and protein expression,
and its primary site: systemic ALK-negative ALCL, systemic ALK-positive ALCL, and
primary cutaneous ALCL [5]. Both ALK-negative and ALK-positive ALCLs involve lymph
nodes and extranodal organs such as skin, soft tissue, liver, and lung. Extranodal sites
other than skin is less frequently involved. The GI tract may be affected secondarily by
systemic ALCL or may be the primary site. Primary GI ALCL is rare and has been reported
in isolated case reports and small case series. In GI tract ALCL, ALK-negative ALCL
is more prevalent [105,106], whereas ALK-positive ALCL is less prevalent [105,107–110]
(approximately 24% of cases according to one report [105]).
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Histologically, large pleomorphic cells proliferate diffusely. These large pleomorphic
cells have irregular, and occasionally horseshoe- or kidney-shaped nuclei and abundant
amphophilic cytoplasm (Figure 4). Lee et al. reported no angiodestruction or geographic
necrosis and no evidence of enteropathies such as intraepithelial lymphocytes or crypt
hyperplasia in background non-neoplastic mucosa [105]. Tumor cells are positive for
CD30 in the Golgi and cytomembrane. In ALK-positive ALCL, the staining pattern varies
depending on the translocation partner of ALK: some cases are positive in the nucleus and
cytoplasm, whereas others are positive in the membrane and cytoplasm. Most cases are
positive for at least one T-cell marker (CD2, CD3, CD4, CD5, and CD7). CD8 is typically
negative, but most cases are positive for one of the cytotoxic markers (TIA-1, granzyme
B, or perforin). OS is significantly better for ALK-positive ALCL than for ALK-negative
ALCL [105,111,112].
Cancers 2021, 13, x  12 of 25 
 
 
by systemic ALCL or may be the primary site. Primary GI ALCL is rare and has been 
reported in isolated case reports and small case series. In GI tract ALCL, ALK-negative 
ALCL is more prevalent [105,106], whereas ALK-positive ALCL is less prevalent [105,107–
110] (approximately 24% of cases according to one report [105]). 
Histologically, large pleomorphic cells proliferate diffusely. These large pleomorphic 
cells have irregular, and occasionally horseshoe- or kidney-shaped nuclei and abundant 
amphophilic cytoplasm (Figure 4). Lee et al. reported no angiodestruction or geographic 
necrosis and no evidence of enteropathies such as intraepithelial lymphocytes or crypt 
hyperplasia in background non-neoplastic mucosa [105]. Tumor cells are positive for 
CD30 in the Golgi and cytomembrane. In ALK-positive ALCL, the staining pattern varies 
depending on the translocation partner of ALK: some cases are positive in the nucleus and 
cytoplasm, whereas others are positive in the membrane and cytoplasm. Most cases are 
positive for at least one T-cell arker (C 2, C 3, C 4, CD5, and CD7). CD8 is typically 
negative, but most cases are positive for one of the cytotoxic markers (TIA-1, granzyme B, 
or perforin). OS is ignificantly better for L -positive  t  for ALK-negative 
ALCL [105,11 , . 
 
Figure 4. Histological and immunohistochemical findings of anaplastic lymphoma kinase (ALK)-positive anaplastic large 
cell lymphoma involving the gastric mucosa. ((a), H&E) Tumor cells are proliferating diffusely in the gastric mucosa. ((b), 
Cytokeratin AE1/AE3) Cytokeratin staining highlights the destruction of the glandular epithelium. ((c), H&E) “Hallmark” 
cells ((indicated by an arrowhead) with horseshoe- or kidney-shaped nuclei are easily found. ((d), ALK) Tumor cells 
showed cytoplasmic staining pattern for ALK. 
6.1.2. Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTCL) 
ENKTCL commonly arises in the nasal cavity or upper aerodigestive tract [5]. The GI 
tract may be affected secondarily as the disease progresses, but primary intestinal presen-
tation has been reported in approximately 6% of cases [113–115]. 
Figure 4. Histological and immunohistochemical findings of anaplastic lymphoma kinase (ALK)-positive anaplastic large
cell lymphoma involving the gastric mucosa. ((a, 20×), H&E) Tumor cells are proliferating diffusely in the gastric mucosa.
((b, 20×), Cytokeratin AE1/AE3) Cytokeratin staining highlights the destruction of the glandular epithelium. ((c, 60×),
H&E) “Hallmark” cells ((indicated by an arrowhead) with horseshoe- or kidney-shaped nuclei are easily found. ((d, 60×),
ALK) Tumor cells showed cytoplasmic staining pattern for ALK.
6.1.2. Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTCL)
ENKTCL commonly arises in the nasal cavity or upper aerodigestive tract [5]. The
GI tract may be affected secondarily as the disease progresses, but primary intestinal
presentation has been reported in approximately 6% of cases [113–115].
Histologically, the size of the tumor cells is variable from small to large, and pleo-
morphic tumor cells are also present (Figure 5). The nuclei of the tumor cells are often
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folded and can be elongated, with granular chromatin and a moderate amount of pale
to clear cytoplasm. An angiocentric/angiodestruction proliferation pattern and necrosis
are often observed. Cases derived from NK cells are usually CD2+, CD3+ (cytoplas-
mic), CD5−, CD4−, CD8−, CD56+, and positive for TIA-1, granzyme B, and perforin.
CD30 expression has been reported to vary but is observed in 26–47% of cases [116–124].
T-cell-derived tumor cells are positive for surface CD3+, CD5+, CD4+, or CD8+, or negative
for both [113,114]. By definition, all cases demonstrate an association with EBV, and in
situ hybridization for EBER demonstrates positive findings in the nuclei of many tumor
cells [114]. Primary intestinal ENKTCL appears to have an inferior prognosis compared to
ENKTCL originating in the upper aerodigestive tract [113,114].
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Figure 5. Histological and immunohistochemical findings of extranodal NK/T cell lymphoma, nasal
type. ((a, 20×, b, 40×), H&E) Dense proliferation of small to medium-sized lymphocytes in the
gastric mucosa. These lymphoid cells are positive for CD8 (c, 40×) and CD56 (d, 40×). Most tumor
cells are positive for EBER in situ hybridization (e, 40×). Ki-67 labeling index is high (f, 40×).
6.1.3. Adult T-Cell Leukemia/Lymphoma (ATLL)
ATLL is a rare T-cell neoplasm caused by chronic infection with the retrovirus human
T-lymphotropic virus type 1 (HTLV-1) [5]. ATLL frequently involves the GI tract, especially
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the stomach. Ishibashi et al. reported that gastric, small intestinal, and large intestinal
ATLL lesions were present in 66%, 18%, and 16% of cases, respectively [125]. ATLL of
primary GI origin without leukemic changes or systemic lymphadenopathy has also been
reported [126–130].
Histologically, medium to large, atypical lymphocytes proliferate diffusely. Primary
gastric ATLL with lymphoepithelial lesions (LELs) have also been reported [129], and such
cases may require attention for differentiation from extranodal marginal zone lymphoma of
mucosa-associated lymphoid tissue (MALT lymphoma), EATL, or MEITL characterized by
lymphocytic infiltration into the epithelium. Typically, tumor cells are CD2+, CD3+, CD4+,
CD8−, CD5+, and CD25+, and CD7 is often negative (Figure 6). Large cells may be CD30+,
which has been observed in 32% of cases of ATLL with GI tract involvement [125]. In such
cases, differentiation from ALCL may be challenging, but ALK is negative. In addition,
CD103 has been reported to be positive in 48% of ATLL with GI tract involvement [125].
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NK-ENT, also known as lymphomatoid gastropathy, is a nonprogressive NK-cell 
proliferation that often mimics intestinal lymphoma as reported by Takeuchi et al. [131]. 
NK-ENT is asymptomatic and is not associated with a history of celiac disease, inflamma-
tory bowel disease, or malabsorption. Many cases have been reported in patients infected 
with H. pylori or those with a history of gastric cancer, and regression has been observed 
in a subset of patients who received eradication therapy for H. pylori. However, a clear 
Figure 6. Histological and im unohistochemical findings of adult T-cell leukemia/lymphoma.
((a, 20×, b, 40×), H&E) Gastric biopsy shows dense infiltration of medium to large-sized atypical
lymphocytes. In high magnification view, tumor cells occasionally show nuclear indentation. Tumor
cells are positive for CD4 (c, 40×) and CD25 (d, 40×).
6.1.4. NK-Cell Enteropathy (NK-ENT)
NK-ENT, also known as lymphomatoid gastropathy, is a nonprogressive NK-cell
proliferation that often mimics intestinal lymphoma as reported by Takeuchi et al. [131]. NK-
ENT is asymptomatic and is not associated with a history of celiac disease, inflammatory
bowel disease, or malabs r tion. Many cases have been reported in patients infect d
with H. pylori or those with a history of gastric cancer, and regression has been observed
in a subset of patients who received eradication therapy for H. pylori. However, a clear
association between H. pylori infection and NK-ENT has yet to be established because
NK-ENT regression is observed even in patients without H. pylori eradication, and a large
proportion of Japanese patients are infected with H. pylori [131].
Histologically, medium-sized atypical lymphocytes diffusely infiltrate the lamina
propria and occasionally infiltrate the glandular epithelium, resembling LEL. Proliferating
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cells typically have round and occasionally irregular nuclei, fine chromatin, inconspicuous
nucleoli, and moderate to abundant clear or eosinophilic cytoplasm. Necrosis may be
present, but angiodestruction is absent. Tumor cells typically exhibit a CD2+/−, cytoplasmic
CD3+, CD4−, CD7+, CD8−, CD56+, CD103−, and TIA1+ phenotype (Figure 7). Rare CD8+
cases have also been reported [132]. Ki-67 labeling index varies among cases and is reported
to be 10–90% [131–135]. EBER in situ hybridization is always negative, distinguishing
this entity from ENKTCL. NK-ENT often regresses spontaneously without treatment, and
malignant transformation has not been reported.
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Figure 7. Histological and immunohistochemical findings of NK-cell enteropathy. ((a, 20×, b, 40×),
H&E) Medium-sized atypical lymphocytes diffusely infiltrate the gastric mucosa. Tumor cells have
irregular nuclei. Tumor cells are positive for CD56 (c, 40×) and TIA-1 (d, 40×). Ki-67 labeling index
is relatively high (approximately 50%) in this case (e, 40×). EBER in situ hybridization is negative
(f, 40×).
Recently, targeted NGS demonstrated recurrent JAK3 mutations in 30% (3/10) of
NK-ENT cases [135].
6.1.5. Chronic Active Epstein-Barr Virus Infection (CAEBV)
CAEBV is usually observed in patients with congenital or acquired immunodefi-
ciency [136,137]. CAEBV is one subtype of EBV-LPD and consists of a spectrum of lym-
phoid diseases including hyperplastic, borderline, and neoplastic diseases [5]. CAEBV
has two types; T/NK-cell type and B-cell type, with the former being majority. Common
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symptoms include abdominal pain, fever, lymphadenopathy and splenomegaly, diarrhea,
or weight loss. Endoscopically, diffuse granular, erythematous mucosa and multiple ulcers
are common findings within the stomach or intestinal tract.
The histological findings vary depending on the grade of CAEBV, ranging from small
to medium-sized lymphoid cells with minimal atypia that are difficult to distinguish from
inflammatory bowel diseases to medium-sized lymphoid cells with mild to moderate
atypia and abnormal T-cell marker expression. In all cases, numerous EBER-positive cells
are observed [138]. Immunohistochemically, CD3+, CD8+, and CD4− phenotypes have
been reported in atypical cells. CD56 is also positive in T/NK-cell types [138].
Differentiating CAEBV from IBD is often challenging, as IBD may be superimposed
with EBV infection. Extranodal NK/T-cell lymphoma should also be considered, as it
shows similar histology and immunostaining results. CAEBV shows systemic symptoms
and abnormal laboratory results from the onset, and the disease gradually worsens with
repeated relapses, whereas NK/T cell lymphoma usually begins as a localized lesion,
but cannot be reliably differentiated by itself. The diagnosis should be made carefully
based on the clinical findings and blood test findings (e.g., EBV DNA copy number).
Early detection of this disease is important because CAEBV can be associated with serious
complications such as disseminated intravascular coagulation syndrome, gastrointestinal
bleeding/perforation, myocarditis, and sepsis, and some patients with CAEBV die within
a few years [138].
6.2. Diagnostic Pitfalls
6.2.1. Discriminating Subtypes with Different Clinical Prognoses
The characteristics of T- and NK-cell lymphomas and lymphoproliferative diseases in
the GI tract are summarized in Table 2. The basic immunostaining combinations that are
recommended are CD20, CD3, CD5, CD4, CD8, CD30, CD56, EBER, and Ki-67, alongside
additional stains such as CD2, CD7, CD103, TIA-1, granzyme B, perforin, MATK, CD79a,
and PAX5, as necessary. The histopathological and immunostaining patterns presented
in Table 2 are representative, and exceptions exist. The following pitfalls should be noted.
The diagnosis should be based on a comprehensive evaluation of clinical information,
including medical history (history of celiac disease or IBD), medication history (presence of
immunosuppressive conditions), serological findings (HTLV-1, anti-tissue transglutaminase
antibody and anti-endomysial antibody), and endoscopic findings.
The following points should be noted:
• Epitheliotropism is more clearly observed with cytokeratin (CK20) staining. Epithe-
liotropism is most frequently observed in EATL and MEITL but is also observed in
other lymphomas or NK-ENT and is not specific to EATL and MEITL.
• EATL with large, atypical cell proliferation with CD30 expression is challenging to
differentiate from ALK-negative ALCL, and a reliable differential approach has not
been established.
• In MEITL, abnormal expression of CD20 is infrequently observed and may lead to
misdiagnosis of B-cell lymphoma. In such cases, other B-cell markers such as CD79a
and PAX5 should be evaluated to prevent misdiagnosis.
• In MEITL, CD8 or CD56 can be negative. CD56 negativity may cause difficulties in
differentiating MEITL from EATL. In the case of CD8-negative MEITL, the immunos-
taining pattern may resemble that of NK-ENT, but the PCR results of NK-ENT do not
exhibit TCR rearrangement.
• MATK is frequently expressed in MEITL, which may support the diagnosis, but is
also reported to be positive in up to 87% of ENKTCL cases [61,114], which should
be noted.
• CD103 expression may represent neoplastic changes in mucosal intraepithelial lym-
phocytes, but it should be noted that approximately half of ATLL cases are also positive
for CD103.
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• Despite NK-ENT being clinically indolent, Ki-67 labeling index has been reported
to be high in some cases. In this situation, high rate of Ki-67 LI is not necessarily an
indicator of aggressive clinical course.
• NK-ENT can be misdiagnosed as ENKTCL, but EBER in situ hybridization will always
show negative results for the former and positive results for the latter.
Table 2. Comparison of the characteristics of gastrointestinal NK- and T-cell lymphoma/lympho-proliferative diseases.
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6.2.2. Distinguishing Primary GI Neoplasms from Secondary Involvement
Detailed history-taking and investigation of systemic lymphadenopathy, paranasal
sinus lesions, skin lesions, and bone marrow lesions are crucial when considering the
primary site of the disease. Imaging techniques such as computed tomography (CT) and
positron emission tomography (PET) scans are also useful for evaluating the distribution
of lesions. When no lymphadenopathy or organ involvement other than the intestinal tract
are noted, the entity is more likely to be a primary GI T- or NK- cell lymphoma. However,
in advanced primary GI tract lymphoma cases, diagnosis is difficult because the lesion
extends outside the GI tract.
6.2.3. Differentiating Neoplasms from Non-Specific Inflammatory Changes at an
Early Stage
In small biopsy specimens, aggressive GI T- and NK- cell lymphoma can be misdi-
agnosed as inflammatory disorders such as celiac disease IBD, lymphocytic colitis, and
autoimmune enteropathy [139]. In particular, when the distant IEL zone of a MEITL lesion
is sampled, it may be challenging to recognize the entity as a lymphoma. In the IEL zone
of MEITL, normal-appearing IEL is positive for CD8 and negative or weakly positive for
CD56 and MATK [58]. It is also necessary to recognize abnormal IEL findings (>20 IELs
per 100 epithelial cells [140]) to diagnose IBD, celiac disease, lymphocytic colitis, EATL,
and MEITL. The IEL is denser in lymphoma with IEL than in inflammatory disorders.
Accordingly, it is crucial to perform a diagnosis by considering endoscopic findings and
medical history.
Differentiating ITLPD-GI from these inflammatory disorders can be more challenging,
as the mucosa may exhibit similar architectural changes and T-cell antigen abnormalities
may not be present. Moreover, occasional epithelioid granulomas have been reported in
patients with ITLPD-GI, which can be misdiagnosed as Crohn’s disease [79,83,141]. In
ITLPD-GI, the lack of a variety of inflammatory cells and the monotonous proliferation of
small lymphoid cells may lead to the recognition of this disease. Endoscopic and serological
findings, immunophenotype, and genetic analysis are helpful, but a high clinical suspicion
is essential to diagnose this subtype of lymphoma.
7. Conclusions
Primary GI T-cell lymphomas include various diseases such as EATL and MEITL,
which have an extremely poor prognosis. In contrast, ITLPD-GI progresses slowly and
is often over-treated. A comprehensive framework that integrates clinical manifestations,
histology, immunostaining results, and genetic data is required for accurate diagnosis. For
any entity included in this group, the optimal treatment strategy needs to be established
using further accumulation of data.
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